← Leaderboards
David Kokel
Massachusetts General Hospital
$3,289,433
Attributed
$4,052,221
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $946.2K · FY2010–17$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$4,052,221 · 3
By mechanism
R01$1,595,928 · 1
U01$1,525,577 · 1
K01$930,716 · 1
Top collaborators
- Jing-Ruey Joanna Yeh4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Schahram Akbarian$48,610,378
- Michael W. Otto$8,919,189
- Mark H Pollack$7,343,315
- Anders M Naar$8,178,903
- Stephen N. Gomperts$8,663,513
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseGenesSmall MoleculeZebrafishBiochemicalBehavioralNervous System DisorderPhenotypeSuccessBiologyGenomeIn VivoIn Vitro AssayIn VitroBrainLigandsNervous System StructureTechnologyGenotypeAnxietyGenome-WideBehavioral ModelDrug DiscoveryBehavior
Grant awards (15)
Behavior-based chemical screening for GABAergic and startle modifying drugs$317,000
R01 · FY2017 · AA · contact PI
Scalable in vivo tools for annotating and manipulating the druggable genome$448,950
U01 · FY2016 · MH
Behavior-based chemical screening for GABAergic and startle modifying drugs$317,000
R01 · FY2016 · AA · contact PI
Scalable in vivo tools for annotating and manipulating the druggable genome$448,950
U01 · FY2015 · MH
Behavior-based chemical screening for GABAergic and startle modifying drugs$307,408
R01 · FY2015 · AA · contact PI
Scalable in vivo tools for annotating and manipulating the druggable genome$174,000
U01 · FY2015 · MH
Scalable in vivo tools for annotating and manipulating the druggable genome$453,677
U01 · FY2014 · MH
Behavior-based chemical screening for GABAergic and startle modifying drugs$306,520
R01 · FY2014 · AA · contact PI
High-throughput behavior-based dopaminergic drug discovery in the zebrafish$112,942
K01 · FY2014 · MH · contact PI
High-throughput behavior-based dopaminergic drug discovery in the zebrafish$73,104
K01 · FY2014 · MH · contact PI
Behavior-based chemical screening for GABAergic and startle modifying drugs$348,000
R01 · FY2013 · AA · contact PI
High-throughput behavior-based dopaminergic drug discovery in the zebrafish$186,046
K01 · FY2013 · MH · contact PI
High-throughput behavior-based dopaminergic drug discovery in the zebrafish$186,046
K01 · FY2012 · MH · contact PI
High-throughput behavior-based dopaminergic drug discovery in the zebrafish$186,046
K01 · FY2011 · MH · contact PI
High-throughput behavior-based dopaminergic drug discovery in the zebrafish$186,532
K01 · FY2010 · MH · contact PI